SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is currently trending amid widespread anticipation of an imminent Executive Order to reclassify cannabis to Schedule III, a move seen by many as a monumental shift for the entire sector. The community is buzzing with speculation about a potential short squeeze, significant institutional investment, and the elimination of 280E tax burdens, while some express caution about a 'sell the news' event or the direct impact on Canadian operators. This potential regulatory change is widely viewed as a foundational step to unlock new opportunities and reshape the cannabis market.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is actively trending following news of its definitive all-stock merger with fusion energy firm TAE Technologies, valued at over $6 billion. This significant pivot into the clean energy sector for AI power is sparking intense debate among the community, with many anticipating a major short squeeze while others view it as another speculative "pump" or "grift".

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is surging amid intense community anticipation of an imminent executive order to reclassify cannabis to Schedule III. Investors are widely discussing the potential elimination of punitive 280E taxes, which would significantly boost profitability and pave the way for institutional capital and uplisting for U.S. multi-state operators, marking a historic shift for the sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron (MU) is trending after delivering a blockbuster earnings report and exceptionally strong guidance, significantly surpassing analyst expectations. This performance is largely driven by robust demand for AI-driven memory, with the company indicating High-Bandwidth Memory (HBM) is fully committed through 2026. The community is actively discussing impressive margin expansion, potential new all-time highs, and numerous analyst price target increases, which is bolstering optimism for the broader AI sector.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is seeing intense trading volatility as natural gas futures prices whipsaw in response to constantly shifting cold and warm weather forecasts. The community is sharply divided between bulls anticipating a strong rebound from recent lows and bears capitalizing on further drops, frequently discussing the ETF's inherent decay and 'widowmaker' reputation.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is a major discussion point as it solidifies its role as a leader in AI infrastructure, propelled by new partnerships and substantial revenue growth targets for its advanced server solutions. However, ongoing volatility sparks polarized community views, with many citing deep undervaluation and market manipulation amidst positive sector news, while others express frustration over the stock's performance despite its strong AI narrative.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is actively trending following news of securing a non-dilutive development loan facility from Macquarie Group to fund new AI data center campuses. This strategic financing is seen by the community as a significant validation, especially with ongoing advanced-stage negotiations for multiple campuses with an investment-grade hyperscaler. Many anticipate this could lead to a substantial rally and potential short squeezes, reinforcing APLD's position as a key player in the expanding AI infrastructure sector.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a significant surge following an earnings beat that highlighted its strategic positioning to meet the escalating power demands of AI data centers. Community discussions are heavily focused on whether the company's natural gas-powered fuel cell technology presents a compelling immediate solution in this booming sector, drawing comparisons to peers. While some investors remain cautious due to historical performance and past dilution, many view this as a pivotal moment for FCEL to capitalize on the AI infrastructure buildout.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors and the community keenly await its upcoming earnings report, with sentiment divided between anticipation for a turnaround driven by strong brand initiatives and upcoming major sports events, and concerns over slowing demand in key international markets. The market is actively debating whether its "Win Now" strategy can overcome competitive pressures and margin challenges.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending due to recent confirmation from the U.S. Department of Transportation that its Santa Ynez Unit pipeline is an interstate facility, shifting regulatory authority to federal oversight. This development has ignited strong bullish sentiment within the community, with many anticipating substantial upside and a potential short squeeze as operational hurdles may diminish. Nevertheless, some market participants remain wary of the company's financial structure and ongoing challenges with state-level approvals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABBV $SLS This mixes real facts with conclusions that don’t follow. Yes, Aza+VEN has struggled in some maintenance and post-transplant settings — largely due to toxicity and patient selection — but that does not mean it “failed broadly” or that those outcomes automatically prove GPS efficacy in REGAL. VIALE-M (CR1), VIALE-T (post-transplant), and VERONA were different populations, different biology, and different trial designs than REGAL’s CR2 maintenance setting.

More importantly, REGAL is an OS-driven, blinded Phase 3 trial. You can’t infer arm-specific benefit or claim GPS is “doing all the heavy lifting” without seeing the hazard ratio and survival curves. Aza+VEN’s limitations are relevant context, but they don’t substitute for REGAL data. If GPS wins, it will be because the Phase 3 OS data show superiority — not because other trials failed elsewhere.

Ehrenhardt

3rddBass

Matthew

Logan Rippenkroger

$SLS Just want to be clear, does Everyone Understand, 
Aza+VEN - the Best Available Treatment (BAT) for the REGAL Phase 3 CONTROL ARM Patients - Recently FAILED 3 Large Phase 3 Trials?  
  
- VERONA - MDS/AML Precursor Trial Failed   
- VIALE-T - AML Post Transplant Maintenance P3 FAILED   
- VIALE-M - AML First Remission CR1 Maintenance P3 FAILED  - all due toxicity - Tracking w Several Dr&#39;s who treat actual P3 RGAL Patients. Including the Dr. Levy - Dir. of Hematological Research at BAYLOR Med. 
 https://viavid.webcasts.com/viewer/event.jsp?ei=1704094&amp;tp_key=e7faa24f6d  
- the VIALE-M CR1 Maintenance trial (TERMINATED NCT Date 08/2025) was an Existential Threat to GPS, currently about to Report Phase 3 Results for CR2 Maintenance.   
  
-- Aza+VEN Failing 3 Phase 3 Trials, including 2 AML Maintenance Trials -  is a pretty big deal - Cost $ABBV near a billion in R&amp;D - and Proves its GPS doing all the heavy lifting Keeping the REGAL P3 patients Alive way longer than anyone imagined. 
//

SELLAS Life Sciences Corporate Update Webinar

StockTwits Web

SELLAS Life Sciences Group Inc

Abbvie Inc

GPs 24 / Control 8

$SLS $ABBV @sninvestor What an Obvious Lying Tool. 
Struggled??? you tool. 3 Large Phase 3 Trials were Terminated - by $ABBV - these were registrational Trials, maybe you short bus tools don&#39;t understand what that means.  
it did fail broadly  
- AML is AML - its the same BIOLOGY. 
- in a very Similar Setting  
- VIALE-M was AML CR1 Ineligible for Transplant  
- REGAL is AML CR2 Ineligible for Transplant  
- AS CLOSE a comp there is.  
and Aza+VEN Killed 23% of the Patients in the VIALE-A trial. . . . https://cdn.clinicaltrials.gov/large-docs/20/NCT04102020/SAP_001.pdf SAP for VIALE-M  
These are some of the Ven + Aza VIALE-A Side Effects

StockTwits for iOS

 This mixes real facts with conclusions that don’t follow. Yes, Aza+VEN has struggled in some maintenance and post-transplant settings — largely due to toxicity and patient selection — but that does not mean it “failed broadly” or that those outcomes automatically prove GPS efficacy in REGAL. VIALE-M (CR1), VIALE-T (post-transplant), and VERONA were different populations, different biology, and different trial designs than REGAL’s CR2 maintenance setting.

More importantly, REGAL is an OS-driven, blinded Phase 3 trial. You can’t infer arm-specific benefit or claim GPS is “doing all the heavy lifting” without seeing the hazard ratio and survival curves. Aza+VEN’s limitations are relevant context, but they don’t substitute for REGAL data. If GPS wins, it will be because the Phase 3 OS data show superiority — not because other trials failed elsewhere.

@sninvestor Fair. The primary endpoint of Regal is OS, which has far surpassed the control arm, such as aza+ven, by several folds, and even more critically, with significantly lower toxicity. As far as the other trials that aza+ven failed, such as Verona, the toxicity did play a huge role, as well as the efficacy. GPS might highly work in those areas, like treating MDS.

The Hooking Bull

The Wolf of Finland

 Fair. The primary endpoint of Regal is OS, which has far surpassed the control arm, such as aza+ven, by several folds, and even more critically, with significantly lower toxicity. As far as the other trials that aza+ven failed, such as Verona, the toxicity did play a huge role, as well as the efficacy. GPS might highly work in those areas, like treating MDS.

Stock Force

@sninvestor just to be clear, I have taken venclexta for a year for CLL. I now have muscle and bone pain from head to toe, facilitations from head to toe a bad heart valve and all kinds of mysterious issues, so what’s your point. I would take GPS in a heart beat but unfortunately it’s too late for me, the constant fatigue and lack of will is a terrible combination. Let’s bring GPS to the forefront, it’s a great alternative to the SOC.

Bpro204

Dean

Shultzy

Jack

Johnny Boys

Chessdoc

 just to be clear, I have taken venclexta for a year for CLL. I now have muscle and bone pain from head to toe, facilitations from head to toe a bad heart valve and all kinds of mysterious issues, so what’s your point. I would take GPS in a heart beat but unfortunately it’s too late for me, the constant fatigue and lack of will is a terrible combination. Let’s bring GPS to the forefront, it’s a great alternative to the SOC.

@sninvestor @Gps_100X_ROI_Potential clearly this is an AI generated response

StockTwits For Android 

 clearly this is an AI generated response

Sausty

@sninvestor @Gps_100X_ROI_Potential 
You obviously havent followed the REGAL trial long enough 
.. how many times has the IDMC ruled.. continue with no changes?

Oh yea, the BAT arm was all accidentally populated by healthy folks who all ran 4 minute miles the day before enrollment..

Give it a break.. sninvestor gets a TURD Block 🚫

K Hoy

 
You obviously havent followed the REGAL trial long enough 
.. how many times has the IDMC ruled.. continue with no changes?

Oh yea, the BAT arm was all accidentally populated by healthy folks who all ran 4 minute miles the day before enrollment..

Give it a break.. sninvestor gets a TURD Block 🚫